This Context Matters Blog piece suggests that the “goal line for drug development is not simply regulatory approval, but rather reimbursement. Incorporating reimbursement intelligence and sensibilities into clinical trial design requires recognizing this goal line and creating a dynamic process to achieve it.” Read more. (Source: Context Matters, 3/10/2014)
